See if blood tests for AD biomarkers help diagnose Alzheimer’s earlier and more accurately
Official title: The BRidge Towards Implementation of Blood-based Biomarkers to Enable Early and Accurate Diagnosis of Alzheimer's Disease (BRIDGE-AD2)
Run by Alzheimercentrum Amsterdam · NCT07680335 · Data updated 2026-11-12
This trial tests whether blood-based biomarkers for Alzheimer's disease can help memory clinics diagnose AD more accurately and quickly for patients with cognitive concerns.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 55 Years and up |
| Sex | All |
| Enrollment | 550 (estimated) |
| Sponsor | Alzheimercentrum Amsterdam Academic / other |
| Locations | 8 sites (Amsterdam, North Holland and 7 other locations) |
| Status | Recruiting |
| Started | September 17, 2025 |
| Main results expected | December 31, 2026 |
| Study ends | June 30, 2027 |
| Registry record updated | July 2, 2026 |
| Trial ID | NCT07680335 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults 55 or older presenting with cognitive complaints in a memory clinic where AD etiology is being considered and who are fluent in Dutch.
✕Probably not a fit
Patients with non-Alzheimer’s cognitive disorders or those outside the age range may not benefit from this biomarker approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The study examines the diagnostic value of blood-based biomarkers, specifically plasma p-tau217 and neurofilament light chain, in a memory clinic setting. It aims to determine how these biomarkers influence clinical decisions and diagnostic accuracy for patients with suspected Alzheimer’s disease. Participants are adults with cognitive complaints who may have AD as the underlying cause, and results will be used to inform etiological diagnosis. The trial is conducted in Dutch memory clinics with collaboration from academic and industry partners to assess real-world utility. No phase designation is provided, and the study focuses on diagnostic utility rather than therapeutic efficacy.
Why it matters
Potential benefit: If successful, BBMs could lead to faster, more accurate diagnoses and more timely access to appropriate care and treatments for patients with suspected AD.
How similar studies have gone: Previous research has shown concordance between BBMs and established AD biomarkers, supporting potential utility, though routine clinical impact in practice remains to be fully demonstrated.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient presents in memory clinic with cognitive complaints. * The physician is concerned about underlying AD as etiology of the complaints. * Adequate fluency in Dutch to understand informed consent procedure. Exclusion Criteria: * Age under 55. * Previous biomarker-confirmed diagnosis of AD. * Alcohol or drug abuse to such an extent that treatment would be advisable. * Patient is incapacitated, and is not able to judge consequences of participation.
Where it's running
-
Amsterdam UMC
Amsterdam, North Holland, Netherlands Recruiting -
Jeroen Bosch Ziekenhuis
's-Hertogenbosch, Netherlands Recruiting -
Flevoziekenhuis
Almere Stad, Netherlands Recruiting -
Spaarne Gasthuis
Haarlem, Netherlands Recruiting -
Tergooi MC
Hilversum, Netherlands Recruiting -
Frisius MC
Leeuwarden, Netherlands Recruiting
Show 2 more locations
-
Dijklander Ziekenhuis
Purmerend, Netherlands Recruiting -
Elisabeth-TweeSteden Ziekenhuis
Tilburg, Netherlands Not yet recruiting
Study contacts
- Study coordinator: Floor Duits, PhD
- Email: f.duits@amsterdamumc.nl
- Phone: 020 - 4440816
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease in Real World Practice
This study will look at real-world safety and effectiveness of disease-modifying therapy (DMT) in adults with MCI or Alzheimer's dementia by comparing those who receive DMT in routine care to those who do not.
-
Automated language analysis to help diagnose neurodegenerative diseases
A multilingual AI-powered language test is being tried to see if speech and language patterns can help differentiate Alzheimer’s, frontotemporal dementia, Lewy body dementia, and Parkinson’s from healthy aging.
-
LIFU to Help Sleep and Amyloid Reduction in Older Adults with Cognitive Impairment
A wearable ultrasound device (ATTN201) is being tested to see if it’s safe and easy to use for people 65 and older with mild cognitive impairment and amyloid buildup.
-
Urolithin A for early Alzheimer’s disease: a test with a nutritional supplement
This trial tests whether taking urolithin A in addition to standard care helps people with early Alzheimer’s or mild cognitive impairment show better biomarkers and cognition.
-
Longitudinal profiling of plasma-derived glial extracellular vesicles in Alzheimer's disease
This study tests whether plasma glial extracellular vesicles and neuroinflammation biomarkers change over time across the Alzheimer’s disease spectrum and whether these signals relate to amyloid, tau, and neurodegeneration, with an additional step of exposing healthy iPSC-derived neurons to vesicles to see potential ne
-
Biomarker Repository for Age-Related and Inherited Neurodegenerative Diseases
This study collects blood and genetic samples from people with neurodegenerative diseases and their families to build a shared resource for studying disease risk and biology.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.